UPDATE | May 22, 2026
Functional validation of S-DUAL® demonstrating a high-yield, stable bispecific antibody platform with robust In vivo anti-tumor activity
Bispecific antibodies (bsAbs) offer significant therapeutic potential, but many existing platforms remain challenged by manufacturability, stability, and development complexity.
This poster demonstrates the developability and functional performance of S-DUAL®, Samsung Biologics’ bispecific antibody platform designed to support high yield, stability, and robust in vivo anti-tumor activity.
Key highlights include:
High yield and purity that support scalable manufacturing
Robust stability that reduces downstream-processing challenges and formulation risks
Improved in vivo potency that may enable lower dosing
Reduced development risk through early validation
Discover how S-DUAL® supports the development of stable, high-performing bispecific antibodies with improved manufacturability and functional performance.
Bispecific antibodies (bsAbs) offer significant therapeutic potential, but many existing platforms remain challenged by manufacturability, stability, and development complexity.
This poster demonstrates the developability and functional performance of S-DUAL®, Samsung Biologics’ bispecific antibody platform designed to support high yield, stability, and robust in vivo anti-tumor activity.
Key highlights include:
- High yield and purity that support scalable manufacturing
- Robust stability that reduces downstream-processing challenges and formulation risks
- Improved in vivo potency that may enable lower dosing
- Reduced development risk through early validation
Discover how S-DUAL® supports the development of stable, high-performing bispecific antibodies with improved manufacturability and functional performance.
Share article
Related Content